Third Security

Fitnet delivers a personal fitness experience to mobile combining biometric sensors, fitness coaching, and online workout buddies. Its unique technological approach converts a mobile webcam into a biometric sensor capable of scoring an individual while they work out with a human trainer. The Fitnet application is used in over 190 countries and its clients have collectively burned over 10 million calories since the launch on January 1, 2014.

Heyo, Inc. was formerly known as Lujure Media, Inc. Heyo helps you easily create Facebook contests, sweepstakes & mobile-optimized landing pages to help you get more fans, leads, and sales. Facebook is the premier network for small businesses and large businesses to grow their communities, and Facebook fan pages help facilitate this growth. Heyo helps companies customize their fan pages using their highly intuitive software. Their Fan Page Builder on Steroids allows users to drag and drop custom Facebook fan pages together in minutes. Mobile is the future. And Heyo is an industry leader in Mobile App development, creating a Breakthrough Mobile App Creator, as well as creating the ability for Facebook fan pages to render on Mobile devices. Heyo makes it super simple to put any kind of message directly into your customers' pockets. Use Heyo to easily create Sweepstakes, Contests, and Campaign apps that publish to Mobile, Facebook, and anywhere on the web. Heyo's Simply Remarkable Website Builder is everything you've ever needed to build your website since you first clicked a mouse (and more!).

Transgenomic, Inc. (Transgenomic) provides products for the purification and analysis of nucleic acids used in the life sciences industry for research focused on molecular genetics and diagnostics. The Company also provides genetic variation analytical services to the medical research, clinical and pharmaceutical markets. Its products and services are categorized as Instrument Related Business and Laboratory Services. It has sold its products to customers in over 50 countries. Customers include numerous academic and medical institutions in the United States and abroad. In addition, its customers also include number of pharmaceutical, biotech and commercial companies both in the United States and abroad. In December 2010, the Company acquired Clinical Data, Inc.'s diagnostic business. ransgenomic, Inc. (www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company is the global leader in cardiac genetic testing with a family of innovative products, including its flagship C-GAAP test, designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.

AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting. We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies. Our plan and success relies on our ability to identify and develop selected phage to eradicate targeted bacterial infections across a wide range of bacterial disease. Initially our phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections. AmpliPhi maintains operations in Richmond, Virginia in the United States, in Colworth Science Park, near London in the United Kingdom, and outside Sydney, NSW, Australia.

Soligenix is a late-stage research and development biopharmaceutical company that focuses on developing products to treat the life-threatening side effects of cancer treatment and serious gastrointestinal diseases where there remains an unmet medical need, as well as developing biodefense vaccines and therapeutics. The company maintains two business segments: BioTherapeutics and BioDefense. Its BioTherapeutics business segment focuses to develop oral beclomethasone dipropionate (orBec or oral BDP) and other biotherapeutic products, including LPMTM Leuprolide. Its BioDefense business segment focuses to convert its ricin toxin vaccine and radiation injury program from early-stage development to advanced development and manufacturing.

Precigen is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Precigen is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Since 1993, Synchrony® has been dedicated to providing world-class products and services that improve performance, size, simplicity and value for rotating machinery.

Cyntellect is dedicated to setting new standards in cell analysis, purification, and processing technology. Cyntellect's products support key applications to advance life science research, biopharmaceutical production, stem cell research and drug discovery. The Company's technology employs in situ, microplate-based cytometry to analyze cells with minimal sample manipulation, and process cells with great precision and efficiency. Cyntellect's expanding cellular analysis and processing portfolio is expected to play an enabling role in the coming age of advanced cell-based diagnostics and therapeutics.

Cyntellect is dedicated to setting new standards in cell analysis, purification, and processing technology. Cyntellect's products support key applications to advance life science research, biopharmaceutical production, stem cell research and drug discovery. The Company's technology employs in situ, microplate-based cytometry to analyze cells with minimal sample manipulation, and process cells with great precision and efficiency. Cyntellect's expanding cellular analysis and processing portfolio is expected to play an enabling role in the coming age of advanced cell-based diagnostics and therapeutics.

Precigen is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

LevelVision designs and deploys video display technologies, and provides marketing solutions to the place-based, ambient, and out-of-home marketing industries.

Since 1993, Synchrony® has been dedicated to providing world-class products and services that improve performance, size, simplicity and value for rotating machinery.

Precigen is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most. Diffusion’s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions. In addition to TSC, Diffusion’s product candidate DFN-529, a novel PI3K/Akt/mTOR pathway inhibitor, is in early-stage development.